Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5997865A · kind A · utility
Inventors
Key dates
| Filing date | May 4, 1995 |
| Grant date | Dec 7, 1999 |
| Priority date | — |
| Expiry date | May 4, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Agonist antibodies are disclosed which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain thereof. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells for example. The antibodies are able to cause primitive hematopoietic cells to proliferate and/or differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are further useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, for example.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.